LL-37 (Cathelicidin Antimicrobial Peptide)

LL-37 is the only member of the cathelicidin family of antimicrobial peptides expressed in humans. Its name comes from its structure: it starts with two leucine residues (LL) and is 37 amino acids long. The full precursor protein, hCAP18 (human cationic antimicrobial protein 18 kDa), is stored in neutrophil granules and cleaved to release active LL-37 at sites of infection and inflammation. The peptide was first characterized in the mid-1990s, and research has exploded since then. A PubMed search returns over 3,000 publications. The initial interest was in its direct antimicrobial properties: LL-37 kills a broad spectrum of gram-positive bacteria, gram-negative bacteria, fungi, and enveloped viruses by physically disrupting their membranes. The mechanism of membrane disruption is elegant. LL-37 folds into an amphipathic alpha-helix, with positively charged residues on one face and hydrophobic residues on the other. The positive charges attract it to negatively charged bacterial membranes (which differ from mammalian cell membranes in their lipid composition). Once bound, the hydrophobic face inserts into the lipid bilayer, creating pores or disrupting membrane organization until the cell dies. Because this mechanism targets fundamental membrane chemistry rather than specific protein targets, bacteria have difficulty developing resistance to it. But the more interesting story is LL-37's role as an immune modulator. A 2004 review in Trends in Immunology (PMID: 14967409) laid out the evidence that LL-37 isn't just a microbial killer. It acts as a chemokine, recruiting neutrophils, monocytes, and T-cells to infection sites. It enhances macrophage phagocytosis. It stimulates angiogenesis in wounds, promoting the blood vessel growth needed for tissue repair. And it modulates cytokine production, dampening some pro-inflammatory signals while enhancing others. The biofilm application is where LL-37 really stands out from conventional antibiotics. Bacterial biofilms (structured communities encased in a protective extracellular matrix) are responsible for chronic infections in sinuses, wounds, and implanted devices. Standard antibiotics often can't penetrate the biofilm matrix. A 2008 study in PLoS ONE (PMID: 18795103) showed that LL-37 at concentrations below its minimum bactericidal concentration could prevent Pseudomonas aeruginosa biofilm formation and break down existing biofilms. This anti-biofilm activity operates through a different mechanism than direct killing: LL-37 affects bacterial motility and communication (quorum sensing) within the biofilm community. The connection to vitamin D is worth noting. Vitamin D is one of the primary regulators of LL-37 expression in the body. When immune cells encounter a pathogen, they upregulate the vitamin D receptor, which then drives LL-37 production. This is one reason why vitamin D deficiency is associated with increased infection susceptibility. Optimizing vitamin D status (typically 40-60 ng/mL of 25-OH-vitamin D) is a logical companion strategy to exogenous LL-37 supplementation. Practical limitations include cost (LL-37 is expensive to synthesize at 37 amino acids) and stability (it's rapidly degraded by proteases in blood, limiting systemic exposure after subcutaneous injection). The local tissue depot effect at the injection site may be more relevant than systemic levels for most applications. Storage requirements include refrigeration at 2-8C after reconstitution, with use within 14-21 days.